BCRX•benzinga•
BioCryst Says ORLADEYO Net Revenue Expected Between $515M-$535M In 2025, Total revenue (Including RAPIVAB) Will Be $540M-$560M
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 10, 2025 by benzinga